Sohini Das

All stories by Sohini Das

Serum Institute set to sign deal with Centre for Covishield

Serum Institute set to sign deal with Centre for Covishield

Rediff.com9 Dec 2020

By January-February, it's expected to have at least 100 million doses for the Indian government, reports Sohini Das.

How Indian pharma bounced back from lockdown lows

How Indian pharma bounced back from lockdown lows

Rediff.com7 Dec 2020

From rising prescriptions to the pharma sales force back on the field with full vigour and companies finally finding their feet with the digital marketing strategies - Indian drug makers have shown that medicine sales is certainly a sunshine sector.

India may get first Covid-19 vaccine by February

India may get first Covid-19 vaccine by February

Rediff.com30 Nov 2020

The government plans to immunise 30 million people in the first phase, starting February, and by July, the target is to vaccinate 250 million people, reports Sohini Das.

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Rediff.com26 Nov 2020

The company has a pipeline of viral vaccines including Zika, dengue, varicella, as well as a potential Covid-19 inoculation.

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Rediff.com13 Nov 2020

'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Rediff.com4 Nov 2020

Siemens Healthineers, one of the largest manufacturers of made-in-India CT scanners, has sold 80-100 such machines in the last 45 days. The medical technology firm typically sells 250 machines in a year.

Bharat Biotech starts Covaxin's at-risk manufacture

Bharat Biotech starts Covaxin's at-risk manufacture

Rediff.com2 Nov 2020

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Why Dr Reddy's had to shut all its units

Why Dr Reddy's had to shut all its units

Rediff.com25 Oct 2020

Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.

Covid-19 impact: Low interest loans likely for vaccine companies

Covid-19 impact: Low interest loans likely for vaccine companies

Rediff.com10 Oct 2020

While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.

Covaxin: How Bharat Biotech plans to boost immunity

Covaxin: How Bharat Biotech plans to boost immunity

Rediff.com6 Oct 2020

Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed.

Covid vaccine: Pharma firms ready expansion plans

Covid vaccine: Pharma firms ready expansion plans

Rediff.com6 Oct 2020

The Indian vaccine industry largely feels there are two ways in which vaccine innovation can be spurred - one, get a high price for the product and two, have the government buy a few hundred million doses of the product at a certain price.

How India is gearing up to distribute Covid-19 vaccine

How India is gearing up to distribute Covid-19 vaccine

Rediff.com18 Sep 2020

A model being considered is to have a combined cold chain approach - where the agricultural cold chain would be combined with vaccine cold chains.

Labs bet on Covid tests for next growth phase

Labs bet on Covid tests for next growth phase

Rediff.com14 Sep 2020

The bouquet of Covid-19 tests that most diagnostic labs are offering include antibody tests (blood tests), rapid antigen tests (point of care tests that detect the presence of an antigen from a nasal or throat swab in case of SARS-CoV-2), and reverse transcription-polymerase chain reaction (RT-PCR) tests.

India will wait for DCGI nod to restart Oxford vaccine trial

India will wait for DCGI nod to restart Oxford vaccine trial

Rediff.com11 Sep 2020

The global trials were halted after a study participant suffered a 'potentially unexplained illness, reports Sohini Das.

In the works: Priority list of who will get Covid vaccine first

In the works: Priority list of who will get Covid vaccine first

Rediff.com4 Sep 2020

The Centre has also contacted five domestic and three multinational vaccine makers to understand how soon a candidate vaccine against Covid-19 will be ready.

Indian pharma firms working on new repurposed drug for Covid-19

Indian pharma firms working on new repurposed drug for Covid-19

Rediff.com2 Sep 2020

Many companies globally are working on plasma research to develop and manufacture hyperimmune globulin therapies from plasma donations.

How India's healthcare system will change forever

How India's healthcare system will change forever

Rediff.com27 Aug 2020

The National Digital Health Mission seeks to provide a unique health ID to each citizen who wishes to have one and also on-board the healthcare service provides - hospitals, pharmacies and diagnostic labs, among others. It will have an online database of doctors and personal health records.

'Cipla has emerged as a great catchment area for talent'

'Cipla has emerged as a great "catchment area" for talent'

Rediff.com20 Aug 2020

An insider said that over the past decade or so Cipla has become immune to the exits of leaders. There have been no directional change in the long-term strategies.

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

Rediff.com19 Aug 2020

The institute expects to complete both, phase-2 and 3 trials in India by the end of this year.

Covid drug sales shine even as market slows

Covid drug sales shine even as market slows

Rediff.com18 Aug 2020

Fabiflu sales have grown by 62 per cent in July. It was launched in June. This drug is being used by doctors for mild-to-moderate Covid patients even if they are in home isolation.

Prev  |  Next